Praxis Precision Medicines, Inc.
NASDAQ•PRAX
CEO: Mr. Marcio Silva De'Souza M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-10-16
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Contact Information
Market Cap
$6.55B
P/E (TTM)
-23.0
17.5
Dividend Yield
--
52W High
$356.00
52W Low
$26.70
52W Range
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$3.52+0.00%
4-Quarter Trend
FCF
-$77.26M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Clinical Milestones Achieved Positive topline results announced for ulixacaltamide Phase 3 Essential3 ET program in Q4 2025; NDA submitted.
Relutrigine NDA Submission EMBOLD study showed positive results for relutrigine in DEEs; NDA submitted, commercial prep underway.
Strong Cash Position Cash, equivalents, and securities totaled $926.1M as of December 31, 2025, funding operations into 2028.
Vormatrigine Phase 2 Success RADIANT Phase 2 study showed positive PK, safety, and efficacy results for vormatrigine in H2 2025.
Risk Factors
Increased Operating Losses Net loss widened to $(303.3M) in 2025 from $(182.8M) in 2024; incurred $249.1M cash burn.
High R&D Expense Growth R&D expenses increased $114.7M to $267.1M in 2025, driven by clinical trial acceleration across platforms.
Need for Future Capital Expect substantial operating expenses to continue; may need additional capital sooner than anticipated.
Regulatory Approval Uncertainty Development subject to lengthy, unpredictable FDA processes; approval for candidates not guaranteed despite positive data.
Outlook
Elsunersen Data Expected Expect topline results for elsunersen EMBRAVE Part A study in H1 2026; EMBRAVE3 Phase 3 results expected 2027.
Vormatrigine Registrational Trials POWER1 topline results expected Q2 2026; POWER2 completion expected H2 2026; plan NDA submission in 2027.
Pipeline Advancement Focus Anticipate nominating development candidates for PRAX-080, PRAX-090, and PRAX-100 in H1 2026.
Commercialization Preparation Plan to expand workforce, focusing on building sales, marketing, and distribution infrastructure for potential launches.
Peer Comparison
Revenue (TTM)
$1.07B
$268.09M
$190.41M
Gross Margin (Latest Quarter)
2763.6%
143.6%
111.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| KYMR | $6.91B | -22.9 | -29.1% | 4.7% |
| PRAX | $6.55B | -23.0 | -58.7% | 0.0% |
| IMVT | $5.23B | -10.1 | -65.8% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 30, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data